CTLA4 and non-small cell lung carcinoma: Dual immune checkpoint blockade targeting PD-1 and CTLA-4 has revolutionized the management of metastatic melanoma and proved effective in other cancers, such as non-small cell lung cancer and renal cell carcinoma1–3.